2499-96-9

Basic information

• Product Name: 4-methyl-5,8,10-triazabicyclo[4.4.0]deca-2,4,11-triene-7,9-dione
• Synonyms: 4-methyl-5,8,10-triazabicyclo[4.4.0]deca-2,4,11-triene-7,9-dione;6-Methylpyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione
• CAS NO: 2499-96-9
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.16
• Mol File: 2499-96-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: >370 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.354g/cm³
• Refractive Index: 1.582
• Storage Temp.: 2-8°C
• PKA: 9.87±0.20(Predicted)
• CAS DataBase Reference: 4-methyl-5,8,10-triazabicyclo[4.4.0]deca-2,4,11-triene-7,9-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-5,8,10-triazabicyclo[4.4.0]deca-2,4,11-triene-7,9-dione(2499-96-9)
• EPA Substance Registry System: 4-methyl-5,8,10-triazabicyclo[4.4.0]deca-2,4,11-triene-7,9-dione(2499-96-9)

Safety Data

• Hazardous Substances Data: 2499-96-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7N3O2/c1-4-2-3-5-6(9-4)7(12)11-8(13)10-5/h2-3H,1H3,(H2,10,11,12,13)

Upstream product

• 932-52-5 5-amino-2,4-dihydroxy-pyrimidine 
• 123-73-9 crotonaldehyde 
• 123-73-9 trans-Crotonaldehyde 
• 932-52-5 5-Aminouracil 
• 53636-71-8 3-amino-6-methylpyridine-2-carboxylic acid 
• 57-13-6 urea 
• 208708-54-7 3-amino-6-methyl-pyrrolo[3,4-c]pyridin-1-one 

Downstream Products

• 30212-52-3 2,4-dichloropyrido<3,2-d>pyrimidine 

Relevant articles and documents

Design, synthesis and biological activity of N5-substituted tetrahydropteroate analogs as non-classical antifolates against cobalamin-dependent methionine synthase and potential anticancer agents

Cobalamin-dependent methionine synthase (MetH) is involved in the process of tumor cell growth and survival. In this study, a novel series of N5-electrophilic substituted tetrahydropteroate analogs without glutamate residue were designed as non-classical antifolates and evaluated for their inhibitory activities against MetH. In addition, the cytotoxicity of target compounds was evaluated in human tumor cell lines. With N5-chloracetyl as the optimum group, further structure research on the benzene substituent and on the 2,4-diamino group was also performed. Compound 6c, with IC50 value of 12.1 μM against MetH and 0.16–6.12 μM against five cancer cells, acted as competitive inhibitor of MetH. Flow cytometry studies indicated that compound 6c arrested HL-60 cells in the G1-phase and then inducted late apoptosis. The molecular docking further explained the structure-activity relationship.

Tetrahydrofurfuroxy folic acid analogue synthetic method

The invention relates to a novel method for synthesis of tetrahydrofolic acid analogues, and mainly solves the problems of uneasily controllable reaction conditions and many produced by products in a conventional synthesis method. A series of tetrahydrofolic acid analogues are prepared by employing 5-aminouracil or 2,4,5,6-tetraaminopyrimidine, 2,5,6-triamino-4-hydroxypyrimidine as an initial raw material and combining the steps of cyclization, oxidation, chlorination, ammonolysis, catalytic hydrogenation reduction, intramolecular cyclization, aziridine ring opening, nucleophilic substitution, ethoxycarbonyl hydrolysis, etc. Compared with a conventional synthesis method, the novel method provided by the invention has the characteristics of mild and stable reaction conditions, few by-products, wide application range, etc.

8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.